Comprehensive research guide to metabolic peptides MOTS-c, AOD-9604, and Tesamorelin. Mechanisms of action, insulin sensitivity, mitochondrial function, and visceral fat metabolism with PubMed citations.
Last updated Aug 7, 2026·11 min read
When metabolic regulation fails, it rarely fails politely. Insulin resistance invites hyperglycemia, hyperglycemia drives dyslipidemia, dyslipidemia accelerates atherosclerosis — a cascade the World Health Organization estimates now touches more than 20% of adults globally, with prevalence still climbing.
Traditional pharmaceuticals fight back one pathway at a time: statins for cholesterol, metformin for glucose, fibrates for triglycerides. Peptide approaches play a different game — rather than blocking single enzymatic steps, they can modulate entire signaling cascades coordinating energy homeostasis across liver, muscle, fat, pancreas, and brain simultaneously.
This guide follows three research peptides attacking metabolism from three altitudes. **MOTS-c MOTS-c mitochondrial-derived peptide (MDP) Mitochondrial-encoded peptide studied for metabolic regulation and longevity ** is a 16-amino-acid peptide encoded within mitochondrial DNA that activates the AMPK pathway — a master metabolic switch governing glucose uptake, fatty acid oxidation, and mitochondrial biogenesis PMID: 25533968 . **AOD-9604 AOD-9604 modified growth hormone fragment peptide Fragment peptide studied for fat metabolism and lipolysis ** is a synthetic growth hormone fragment (amino acids 177–191) that stimulates lipolysis through β3-adrenergic receptor engagement without touching insulin-like growth factor 1 (IGF-1) levels PMID: 11739441 . **Tesamorelin Tesamorelin growth hormone-releasing hormone (GHRH) analog GHRH analogue studied for visceral fat reduction and GH-axis stimulation ** — the only FDA-approved compound here — is a synthetic GHRH analogue that reduces visceral adipose tissue with documented effects on hepatic fat and lipid profiles PMID: 20101189 .
Read together, they illustrate where peptide science is heading: treating metabolic dysfunction not as one problem but as a network of interconnected ones — intracellular fuel sensing, adipocyte lipid handling, endocrine signaling.
By the end you'll know each compound's discovery story, mechanism, evidence depth, and the honest gaps between them. Standard frame applies throughout: educational resource grounded in preclinical and clinical literature — not guidance for human use, treatment, or diagnosis.
Start at the deepest level: inside the mitochondrion itself.
I.Overview
Metabolic regulation is not one process but a relay spanning organs. The liver manages glucose production and lipid synthesis; skeletal muscle handles most glucose disposal; adipose tissue stores and releases fatty acids on hormonal command; the pancreas conducts the whole ensemble through insulin and glucagon.
Peptide research maps onto that relay at three distinct levels — and the level determines both opportunity and risk.
1. Mitochondrial Metabolic Signaling (AMPK Activation) — the intracellular floor. AMP-activated protein kinase acts as the cell's fuel gauge: when ATP drops during exercise, caloric restriction, or metabolic stress, AMPK ramps up catabolic ATP-generating pathways and throttles anabolic consumers. MOTS-c MOTS-c mitochondrial-derived peptide (MDP) Mitochondrial-encoded peptide studied for metabolic regulation and longevity , the mitochondrial-derived peptide, translocates to the nucleus under metabolic stress and activates AMPK signaling, potentially reproducing some of exercise's molecular signature PMID: 25533968 .
2. Direct Adipocyte Lipid Mobilization (β3-Adrenergic Pathway) — the fat-cell level. Some peptides skip systemic sensing entirely and talk to adipocytes directly. AOD-9604 AOD-9604 modified growth hormone fragment peptide Fragment peptide studied for fat metabolism and lipolysis stimulates lipolysis by heightening catecholamine sensitivity through β3-adrenergic receptors, mobilizing stored triglycerides without engaging the GH receptor or raising IGF-1 — separating the fat-mobilization signal from growth hormone's metabolic baggage PMID: 11739441 .
3. GH/IGF-1 Axis Modulation (GHRH Signaling) — the endocrine level. Tesamorelin Tesamorelin growth hormone-releasing hormone (GHRH) analog GHRH analogue studied for visceral fat reduction and GH-axis stimulation stimulates pulsatile endogenous GH release, which preferentially mobilizes visceral fat through GH-mediated lipolysis. Because GHRH analogues preserve physiological pulsatility rather than forcing constant GH exposure, they may sidestep some adverse metabolic effects of direct GH administration PMID: 20101189 .
Altitude is the organizing insight: MOTS-c MOTS-c mitochondrial-derived peptide (MDP) Mitochondrial-encoded peptide studied for metabolic regulation and longevity changes how individual cells handle fuel, AOD-9604 AOD-9604 modified growth hormone fragment peptide Fragment peptide studied for fat metabolism and lipolysis empties fat cells directly, Tesamorelin Tesamorelin growth hormone-releasing hormone (GHRH) analog GHRH analogue studied for visceral fat reduction and GH-axis stimulation redirects a hormonal cascade touching every tissue at once. Each altitude also answers a different research question — cellular efficiency, fat availability, hormonal tone — which is exactly why combination logic gets complicated fast, as the synergy section details.
MOTS-c MOTS-c mitochondrial-derived peptide (MDP) Mitochondrial-encoded peptide studied for metabolic regulation and longevity (Mitochondrial ORF of the Twelve S c) rewrote a textbook assumption. Encoded within the 12S rRNA gene of mitochondrial DNA, this 16-amino-acid peptide was identified in 2015 by Changhan David Lee's group at the University of Southern California — and its existence meant mitochondrial DNA encodes more than electron transport chain components: it encodes signaling peptides that talk back to the nucleus, regulating gene expression from within PMID: 25533968 .
That discovery opened an entire field of mitochondrial-derived peptides (MDPs), with MOTS-c MOTS-c mitochondrial-derived peptide (MDP) Mitochondrial-encoded peptide studied for metabolic regulation and longevity and humanin as flagship members. For a molecule nobody knew existed a decade ago, its publication record has grown remarkably fast.
The core mechanism is AMPK activation, and the imagery writes itself. When cellular energy status drops — exercise, caloric restriction, metabolic stress — MOTS-c MOTS-c mitochondrial-derived peptide (MDP) Mitochondrial-encoded peptide studied for metabolic regulation and longevity leaves the mitochondrion, enters the nucleus, and flips the AMP-activated protein kinase switch PMID: 25565208 : the fuel gauge that fires up ATP-generating pathways while suppressing anabolic consumers.
Downstream, the cascade reads like an exercise prescription: increased glucose uptake via GLUT4 translocation to the cell membrane, enhanced fatty acid oxidation, suppressed lipogenesis, inhibited mTOR — the anabolic pathway promoting fat storage when overactivated.
The foundational mouse studies delivered proof of concept. MOTS-c MOTS-c mitochondrial-derived peptide (MDP) Mitochondrial-encoded peptide studied for metabolic regulation and longevity treatment prevented diet-induced obesity and improved glucose tolerance without reducing food intake — meaning the effect was purely metabolic, not appetite-driven PMID: 25533968 . Follow-up work confirmed improved metabolic homeostasis and reduced insulin resistance in diet-induced obesity models, touching both glucose and lipid metabolism PMID: 25738459 .
Exercise interaction is the liveliest frontier. MOTS-c MOTS-c mitochondrial-derived peptide (MDP) Mitochondrial-encoded peptide studied for metabolic regulation and longevity rises in skeletal muscle after physical activity, and research suggests genuine synergy: the peptide engages exercise-responsive regulation of PGC-1α, attenuating insulin resistance and enhancing glucose metabolism through AMPK signaling PMID: 33288600 . A 2022 study found MOTS-c increases with long-term training and even improves acute exercise performance after a single dose PMID: 35929232 — hence the "exercise mimetic" label, though the data suggests it works alongside exercise rather than replacing it. Put practically: a runner's muscles are already running this program.
Recent findings widen the aperture beyond classic metabolic syndrome. A 2025 study in Experimental & Molecular Medicine reported that MOTS-c MOTS-c mitochondrial-derived peptide (MDP) Mitochondrial-encoded peptide studied for metabolic regulation and longevity prevents pancreatic islet cell senescence, potentially delaying diabetes onset through a route independent of insulin sensitivity [Nature 2025]; another 2025 paper showed it combats diabetic liver fibrosis by targeting the Keap1-Nrf2-Smad2/3 pathway PMID: 40425777 — protective signals across multiple metabolic disease pathways.
One limitation caps everything else: near-zero human clinical data. Every efficacy result to date comes from animal models or cell culture, rodent-to-human translation in metabolism is famously uncertain, and MOTS-c MOTS-c mitochondrial-derived peptide (MDP) Mitochondrial-encoded peptide studied for metabolic regulation and longevity 's minutes-long half-life raises real bioavailability questions for any clinical future.
Next: the compound that tried to keep growth hormone's fat-burning while deleting its baggage.
AOD-9604 AOD-9604 modified growth hormone fragment peptide Fragment peptide studied for fat metabolism and lipolysis is an exercise in subtraction. Take human growth hormone's 191 amino acids, keep only the C-terminal tail — residues 177–191, plus a tyrosine substitution at position 176 — and discard everything else. Frank Ng's group at Monash University established the logic: the lipolytic (fat-breaking) activity of GH lives in this specific region, while growth-promoting and diabetogenic effects are encoded elsewhere in the molecule PMID: 11739441 .
The rationale is seductive. Full-length growth hormone mobilizes fat powerfully but drags IGF-1 elevation, insulin resistance, and acromegalic risks behind it. Isolate just the lipolytic signal and the benefit column stays clean.
Mechanistically, AOD-9604 AOD-9604 modified growth hormone fragment peptide Fragment peptide studied for fat metabolism and lipolysis stimulates lipolysis by enhancing adipocyte sensitivity to catecholamines through β3-adrenergic receptors, predominantly expressed on white adipose tissue. Downstream, hormone-sensitive lipase (HSL) and perilipin-mediated lipid droplet breakdown free fatty acids from stored triglycerides PMID: 11739441 .
A 2001 knockout-mouse study tightened the story further. Obese mice given either full-length GH or AOD-9604 AOD-9604 modified growth hormone fragment peptide Fragment peptide studied for fat metabolism and lipolysis raised β3-adrenergic receptor RNA expression to lean-mouse levels; in β3-AR knockout mice, long-term treatment produced no body-weight or lipolysis changes — confirming the receptor's central role. Yet in acute experiments AOD-9604 still boosted energy expenditure and fat oxidation in knockouts, hinting at a secondary β3-independent mechanism PMID: 11713213 .
Metabolic cleanliness is the distinguishing claim. Across preclinical studies, AOD-9604 AOD-9604 modified growth hormone fragment peptide Fragment peptide studied for fat metabolism and lipolysis did not elevate blood glucose, insulin, or IGF-1 levels PMID: 11739441 , confirming separation from full-length GH activity, and induced no insulin resistance in any study — a pointed contrast, since GH-induced insulin resistance remains among the most problematic side effects of growth hormone therapy.
Human results, though, cooled quickly. A Phase 2 trial in 300 obese adults ran 12 weeks: the top dose (1 mg/day) achieved statistically significant weight loss versus placebo — modest in effect size. A subsequent 24-week trial in 536 subjects then failed to replicate the finding under intensive diet-and-exercise conditions, and development was discontinued in 2007 [PMC3584306]. No Phase 3 trials followed.
One footnote matters for detection contexts: a 2015 study characterized AOD-9604 AOD-9604 modified growth hormone fragment peptide Fragment peptide studied for fat metabolism and lipolysis 's in-vitro metabolic profile relevant to anti-doping analysis — the compound is WADA-prohibited as a potential performance-enhancing substance PMID: 25208511 .
An elegant mechanism, a stalled clinical arc — the exact inverse of the compound coming next.
Tesamorelin Tesamorelin growth hormone-releasing hormone (GHRH) analog GHRH analogue studied for visceral fat reduction and GH-axis stimulation is the only member of this guide that finished the race. A synthetic 44-amino-acid analogue of growth hormone-releasing hormone, it won FDA approval in 2010 under the brand name Egrifta for reducing excess visceral abdominal fat in HIV-infected patients with lipodystrophy PMID: 20101189 — completed Phase 3 trials, post-market surveillance, an established safety profile. No other metabolic peptide here can claim any of that.
Context helps: antiretroviral therapy redistributes fat severely, piling visceral fat into the abdomen while the face and limbs waste away. Tesamorelin Tesamorelin growth hormone-releasing hormone (GHRH) analog GHRH analogue studied for visceral fat reduction and GH-axis stimulation 's approval addressed precisely that population — narrow, well-defined, and metabolically unusual.
The mechanism runs the classic GH axis. Binding GHRH receptors on pituitary somatotrophs raises cAMP and triggers pulsatile GH synthesis and release; GH then drives hepatic IGF-1 production, mediating peripheral effects on muscle, bone, and adipose tissue. In fat specifically, GH stimulates lipolysis — upregulating hormone-sensitive lipase, enhancing catecholamine sensitivity, promoting fatty acid oxidation — and visceral fat responds disproportionately, explaining why effects concentrate in abdominal VAT rather than subcutaneous depots PMID: 20101189 .
Numbers from the pivotal Phase 3 trial: 412 HIV-positive patients with excess visceral fat, randomized to tesamorelin Tesamorelin growth hormone-releasing hormone (GHRH) analog GHRH analogue studied for visceral fat reduction and GH-axis stimulation 2 mg or placebo for 26 weeks. Result — visceral adipose tissue down approximately 18%, subcutaneous fat essentially untouched, waist circumference down 3.4 cm on average PMID: 20101189 . Depot-selective reduction, not generalized weight loss.
Liver effects got their own randomized trial: across 48 HIV patients, six months of treatment cut VAT by 42 cm² and liver fat by 2.0% in lipid-to-water ratio (P = .003), with fasting glucose spiking transiently at two weeks before normalizing by month six PMID: 25038357 .
Beyond HIV, a randomized controlled trial in obese subjects with reduced GH secretion showed improved body composition and reduced trunk fat, with metabolic effects comparable to those seen in HIV patients — suggesting broader applicability [PMC3513535]. A 2026 meta-analysis of five RCTs consolidated the record: VAT −27.71 cm², trunk fat −1.18 kg, hepatic fat −4.28%, waist −1.61 cm, plus the expected IGF-1 increase PMID: 41545261 .
Glucose remains the watch-item. Short-term studies showed minimal insulin-sensitivity change, and a 2017 trial in type 2 diabetes patients found tesamorelin Tesamorelin growth hormone-releasing hormone (GHRH) analog GHRH analogue studied for visceral fat reduction and GH-axis stimulation safe in this population but without significant glycemic improvement — GH-mediated metabolism is complicated and does not automatically improve blood sugar PMID: 28630297 .
From a proven drug back to the research frontier: what actually happens when three different altitudes try to work together?
fat-loss metabolic-health muscle-growth
III.How They Work Together
Three compounds, three altitudes — and the interesting question is whether the altitudes compose.
MOTS-c MOTS-c mitochondrial-derived peptide (MDP) Mitochondrial-encoded peptide studied for metabolic regulation and longevity works intracellularly: AMPK activation shifts every receiving cell toward burning mode — more GLUT4-mediated glucose uptake, more fatty acid oxidation, less lipogenesis, mTOR dialed down. The effects are cell-autonomous, aggregating into tissue-level efficiency: muscle burns more fat, liver exports less glucose, adipocytes bank less triglyceride PMID: 25533968 .
AOD-9604 AOD-9604 modified growth hormone fragment peptide Fragment peptide studied for fat metabolism and lipolysis works at the fat cell itself: β3-adrenergic stimulation mobilizes stored triglyceride without touching appetite, insulin secretion, or GH levels — a strictly peripheral mechanism, independent of the central nervous system entirely PMID: 11739441 .
Tesamorelin Tesamorelin growth hormone-releasing hormone (GHRH) analog GHRH analogue studied for visceral fat reduction and GH-axis stimulation works endocrinologically: a systemic hormonal cascade through GH/IGF-1 hitting multiple organ systems at once, visceral fat as the privileged target, IGF-1 elevation riding along PMID: 20101189 .
Stacked logically, the trio composes neatly: AOD-9604 AOD-9604 modified growth hormone fragment peptide Fragment peptide studied for fat metabolism and lipolysis releases fat from storage, MOTS-c MOTS-c mitochondrial-derived peptide (MDP) Mitochondrial-encoded peptide studied for metabolic regulation and longevity biases cells toward oxidizing what was released, Tesamorelin Tesamorelin growth hormone-releasing hormone (GHRH) analog GHRH analogue studied for visceral fat reduction and GH-axis stimulation strips visceral fat through a wholly separate hormonal channel. Address cellular energy sensing, adipocyte mobilization, and endocrine modulation simultaneously — and in theory you get effects no single agent produces alone.
Theory is where it stops. No controlled study has tested any combination of these three compounds — in any species. The most-studied metabolic peptide pairing, CJC-1295 CJC-1295 growth hormone releasing hormone (GHRH) analogue Growth hormone-releasing hormone analogue plus Ipamorelin Ipamorelin growth hormone secretagogue (GHS) / selective ghrelin receptor agonist Selective growth hormone secretagogue , stays within a single mechanistic family (both GH-axis agents); cross-altitude combinations remain unstudied territory.
Safety geometry adds friction too: Tesamorelin Tesamorelin growth hormone-releasing hormone (GHRH) analog GHRH analogue studied for visceral fat reduction and GH-axis stimulation 's GH mediation brings IGF-1 elevation that AOD-9604 AOD-9604 modified growth hormone fragment peptide Fragment peptide studied for fat metabolism and lipolysis and MOTS-c MOTS-c mitochondrial-derived peptide (MDP) Mitochondrial-encoded peptide studied for metabolic regulation and longevity lack. Combining it with other compounds could amplify GH-related effects — insulin resistance, fluid retention, joint pain — in ways single-compound studies cannot predict. That uncertainty is a genuine barrier to combination research, not a technicality.
So the practical takeaway is disciplined humility: three mechanisms validated at their own levels, zero validated synergies. Before combination speculation comes the pragmatic layer — routes, doses, timelines — which the next section lays out.
IV.Frequently Asked Questions
Frequently Asked Questions
The distinction is one of focus rather than substance. Weight loss peptides are studied primarily for their effects on body weight and fat mass — the outcome is a number on a scale. Metabolic peptides are studied for their effects on the underlying processes that regulate energy metabolism — insulin sensitivity, glucose homeostasis, lipid profiles, mitochondrial function, and fat distribution. Some compounds appear in both categories: MOTS-c and AOD-9604 affect both body composition and metabolic markers. The metabolic peptides guide emphasizes the mechanistic and metabolic health aspects rather than weight loss efficacy.
AMPK (AMP-activated protein kinase) is a cellular energy sensor that activates when ATP levels drop. MOTS-c, a mitochondrial-derived peptide, translocates from the mitochondria to the nucleus during metabolic stress and activates AMPK signaling [PMID: 25565208]. AMPK activation increases glucose uptake via GLUT4 translocation, enhances fatty acid oxidation, suppresses lipogenesis (new fat synthesis), and inhibits mTOR (an anabolic pathway). This cascade shifts cellular metabolism from storage mode to utilization mode. In animal models, this prevented diet-induced obesity without reducing food intake [PMID: 25533968]. The relevance to metabolic health is that impaired AMPK signaling is implicated in insulin resistance, type 2 diabetes, and non-alcoholic fatty liver disease.
The key evidence comes from the Monash University preclinical studies. In obese mouse models, AOD-9604 reduced body fat mass without elevating blood glucose, insulin, or IGF-1 levels — confirming separation from full-length GH activity [PMID: 11739441]. The mechanism involves β3-adrenergic receptor activation on adipocytes rather than GH receptor engagement. A 2001 study confirmed that AOD-9604 increases β3-AR RNA expression in obese mice to lean levels, and that β3-AR knockout mice do not respond to long-term AOD-9604 treatment [PMID: 11713213]. However, human clinical data is limited to a single Phase 2 trial (n=300, 12 weeks) with modest results, and a subsequent 24-week trial that failed to replicate the finding.
Visceral adipose tissue appears to be preferentially responsive to growth hormone-mediated lipolysis. Visceral fat has a higher density of GH receptors and hormone-sensitive lipase compared to subcutaneous fat. Additionally, visceral fat drains directly into the portal circulation, so its reduction has immediate metabolic benefits — fewer free fatty acids reaching the liver, improved hepatic insulin sensitivity, and reduced triglyceride synthesis. In the pivotal Phase 3 trial, tesamorelin reduced visceral fat by approximately 18% without significantly affecting subcutaneous fat [PMID: 20101189]. A 2026 meta-analysis of five RCTs confirmed reductions of 27.71 cm² in visceral fat and 4.28% in hepatic fat [PMID: 41545261].
The evidence varies by compound. MOTS-c has the strongest preclinical evidence — it improved glucose tolerance and reduced insulin resistance in diet-induced obesity models without reducing food intake [PMID: 25533968], and a 2025 study showed it prevents pancreatic islet cell senescence [Nature 2025]. AOD-9604 did not cause insulin resistance in any study, but its effect on improving insulin sensitivity has not been specifically demonstrated. Tesamorelin's effects on glucose are complex: a 2017 trial in type 2 diabetes patients found it safe but without significant glycemic improvement [PMID: 28630297]. The most robust clinical evidence for metabolic improvement comes from tesamorelin's reduction of hepatic fat, which is a known contributor to hepatic insulin resistance.
No controlled studies of these specific combinations exist. The theoretical rationale is reasonable: GLP-1 agonists reduce appetite and improve insulin secretion centrally, while metabolic peptides target different pathways — AMPK activation (MOTS-c), direct lipolysis (AOD-9604), and GH-mediated visceral fat reduction (tesamorelin). However, combination safety data is absent. Tesamorelin's IGF-1 elevation could interact with GLP-1 agonist effects on insulin secretion in unpredictable ways. Any combination research would require careful pharmacokinetic and safety monitoring.
Metformin works primarily by activating AMPK indirectly — through inhibition of mitochondrial complex I, which raises the AMP:ATP ratio. MOTS-c activates AMPK through a different mechanism (nuclear translocation and transcriptional regulation). AOD-9604 and tesamorelin work through entirely different pathways (β3-adrenergic and GH/IGF-1 respectively) that have no overlap with metformin. The key difference is that established metabolic drugs are approved, well-characterized, and have decades of safety data. Metabolic peptides are research compounds with limited human data, and none are approved for metabolic indications outside tesamorelin's specific HIV lipodystrophy approval.
MOTS-c MOTS-c mitochondrial-derived peptide (MDP) Mitochondrial-encoded peptide studied for metabolic regulation and longevity , AOD-9604 AOD-9604 modified growth hormone fragment peptide Fragment peptide studied for fat metabolism and lipolysis , and Tesamorelin Tesamorelin growth hormone-releasing hormone (GHRH) analog GHRH analogue studied for visceral fat reduction and GH-axis stimulation amount to three answers to one question — how do you intervene in metabolism — given at three biological altitudes: intracellular energy sensing (AMPK), adipocyte lipid mobilization (β3-AR), and systemic endocrine regulation (GH axis).
Established: each compound is biologically active in its own lane. MOTS-c MOTS-c mitochondrial-derived peptide (MDP) Mitochondrial-encoded peptide studied for metabolic regulation and longevity activates AMPK signaling and prevents diet-induced obesity in animal models PMID: 25533968 ; AOD-9604 AOD-9604 modified growth hormone fragment peptide Fragment peptide studied for fat metabolism and lipolysis drives lipolysis through β3-adrenergic receptors without elevating IGF-1 PMID: 11739441 ; Tesamorelin Tesamorelin growth hormone-releasing hormone (GHRH) analog GHRH analogue studied for visceral fat reduction and GH-axis stimulation cuts visceral and hepatic fat in controlled human trials as the trio's only FDA-approved member PMID: 20101189 .
Not established: whether these compounds combine safely or effectively, whether rodent metabolic benefits survive translation to human outcomes, or whether metabolic peptides can reach aspects of metabolic syndrome that existing pharmaceuticals miss.
One distinction deserves the last word: weight loss and metabolic health are not synonyms. GLP-1 receptor agonists out-loss anything in this guide on the scale — yet mitochondrial function, visceral fat distribution, and hepatic steatosis are dimensions appetite-suppressing drugs don't directly target. Whether that theoretical niche becomes clinical advantage is precisely the open question.
Continue with the Weight Loss Peptides guide for the scale-focused angle; compound profiles live at [MOTS-c MOTS-c mitochondrial-derived peptide (MDP) Mitochondrial-encoded peptide studied for metabolic regulation and longevity ](/en/compounds/mots-c/), [AOD-9604 AOD-9604 modified growth hormone fragment peptide Fragment peptide studied for fat metabolism and lipolysis ](/en/compounds/aod-9604/), and [Tesamorelin Tesamorelin growth hormone-releasing hormone (GHRH) analog GHRH analogue studied for visceral fat reduction and GH-axis stimulation ](/en/compounds/tesamorelin/); comparisons at AOD-9604 vs MOTS-c and AOD-9604 vs Tesamorelin; primary literature via PubMed.
Whichever altitude interests you most, you now hold the map showing all three.
AOD-9604 
MOTS-c mitochondrial-derived peptide (MDP) Mitochondrial-encoded peptide studied for metabolic regulation and longevity (Mitochondrial ORF of the Twelve S c) rewrote a textbook assumption. Encoded within the 12S rRNA gene of mitochondrial DNA, this 16-amino-acid peptide was identified in 2015 by Changhan David Lee's group at the University of Southern California — and its existence meant mitochondrial DNA encodes more than electron transport chain components: it encodes signaling peptides that talk back to the nucleus, regulating gene expression from within PMID: 25533968 .
CJC-1295 
Ipamorelin